Merck & Co., Inc. Declared Positive Results from Vytorin study NYSE:MRK

Merck & Co., Inc. announced on Saturday, 19th November, that its new study showed positive results about the usage of its cholesterol drug Vytorin. The usage of this drug helps in reducing the risk of heart attack. It also helps in reducing the need of heart surgeries in chronic kidney patients by 16%. The study was conducted by Oxford University in which more than 9000 patients were examined who had advanced or end-stage chronic kidney disease. Merck declared that with these strong results in the improvement of patients the drug will be presented for approval to use it for kidney diseases. Merck also declared that the result is considerable because kidney patients have high risk of vascular disease. With the approval of this medicine it will help company to compete in the market above its competitors. Merck & Co., Inc. (Merck) is a global health care company that delivers health solutions through its medicines, vaccines, biologic therapies, and consumer and animal products, which it markets directly and through its joint ventures. The Company's operations are principally managed on a products basis. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
tdp2664Penny Stock Live